ABBV 63.27 Abbvie Inc. Common Stock $ABBV Hit a 52 week

New Post Public Reply Private Reply Replies (0) Message Board

Nov 14, 2014 at 10:05 AM

ABBV 63.27 Abbvie Inc. Common Stock $ABBV Hit a 52 week high of 63.99 Closing the day 09:45 at 63.27 -0.36 -0.57% With a day low of 63.22 and a total volume of 333,039.

ABBV Recent Posts: http://investorshangout.com/AbbVie-Inc-ABBV-90091/

ABBV Abbvie Inc. Common Stock Recent Headline News

Where Will Google Stock Be in 10 Years?
Leo Sun, The Motley Fool - Motley Fool - 1 hr 4 mins ago
Over the past decade, Google stock has soared over 500%, fueled by the growth in search and mobile devices. Google now controls 58% of the world's Internet searches and 85% of the mobile market via Android, and it continues to disrupt Microsoft'...
AMZN: 321.64 (+5.16), FB: 74.36 (+0.11), ABBV: 63.25 (-0.38), GOOGL: 553.63 (-2.81), GOOG: 543.15 (-2.23)

The Post AASLD Annual Meeting Hepatitis C Landscape
Leonard Yaffe - at Seeking Alpha - Fri Nov 14, 5:15AM CST

JNJ: 108.69 (-0.38), GILD: 102.12 (-2.08), MRK: 59.34 (-0.20), ABBV: 63.25 (-0.38)

If Gilead Has The Ace, Is AbbVie Holding The Big Joker?
Shock Exchange - at Seeking Alpha - Fri Nov 14, 1:55AM CST

GILD: 102.12 (-2.08), ABBV: 63.25 (-0.38)

Is Johnson & Johnson A Stock Worth Having In The Portfolio Right Now?
Abba's Aces - at Seeking Alpha - Fri Nov 14, 1:36AM CST

JNJ: 108.69 (-0.38), PFE: 30.47 (+0.05), ABBV: 63.25 (-0.38)

AbbVie's Leadership in Immunology Featured at 2014 American College of Rheumatology Annual Meeting with New Data on Investigational Medicines and HUMIRA® (adalimumab)
PR Newswire - Thu Nov 13, 8:00AM CST
AbbVie (NYSE: ABBV) announced that data from 37 abstracts related to HUMIRA® (adalimumab), rheumatologic diseases and investigational medicines will be presented at the upcoming 2014 American College of Rheumatology (ACR) Annual Meeting, November 14 - 19, in Boston. As a long-standing expert in the field of rheumatology with its experience with HUMIRA, AbbVie continues to build on its leadership with data focused on investigational medicines to create innovative solutions for rheumatologic diseases.
ABBV: 63.25 (-0.38)

Testosterone Sales Slump as Testosterone Lawsuit MDL Builds Momentum, Report Attorneys Handling National Testosterone Lawsuits
PRWeb - Thu Nov 13, 2:22AM CST
Lawyers providing legal representation for testosterone lawsuits report progress in the national multidistrict litigation for testosterone lawsuits; meanwhile, a major news source, Bloomberg Businessweek, reported on losses in the testosterone replacement therapy market. These attorneys offer timely testosterone lawsuit news updates and testosterone lawsuit case review at androgeltestosteronelawsuitcenter.com.
PFE: 30.47 (+0.05), ABBV: 63.25 (-0.38)

Achillion Pharmaceuticals: Still Bullish, But Taking Profits
Dr. Paul Nunzio DeSantis, Pharm.D - Seeking Alpha - Wed Nov 12, 4:06PM CST
By Dr. Paul Nunzio De Santis (Pharm.D.) Entry: $9.86 10/2/14 Take Profits: $14.45 11/12/14 Hold 10-20% of profits into event for M&A upside. Achillion (NASDAQ: ACHN ) has been a stellar performer since we wrote about it on October 2nd- up...
ACHN: 13.87 (+0.38), MRK: 59.34 (-0.20), ABBV: 63.25 (-0.38)

Gilead Reports Promising Data on its HCV Drug Harvoni - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 4:00PM CST
Gilead Sciences, Inc. (GILD) announced pooled data from certain phase II and phase III studies evaluating Harvoni.
AGN: 196.51 (+0.30), JNJ: 108.69 (-0.38), GILD: 102.10 (-2.10), ABBV: 63.25 (-0.38)

Gilead Sciences Gets Ambushed By The Patent Troll, AbbVie
Small Pharma Analyst - at Seeking Alpha - Wed Nov 12, 2:25PM CST

GILD: 102.10 (-2.10), ABBV: 63.25 (-0.38)

Regeneron/Sanofi Announce Positive Dupilumab Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 10:00AM CST
Regeneron Pharmaceuticals, Inc. (REGN) and partner Sanofi (SNY) announced encouraging data from the interim analysis of a dose-ranging phase IIb study on dupilumab.
AGN: 196.51 (+0.30), ABBV: 63.25 (-0.38), SNY: 46.33 (-0.20), REGN: 399.88 (-2.75)

Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 12, 7:48AM CST
Companies like AbbVie (ABBV), Gilead (GILD) and Achillion (ACHN) had a strong presence at the annual Liver Meeting.
VRTX: 112.37 (-0.35), GILD: 102.13 (-2.07), ACHN: 13.88 (+0.39), DNDN: 0.12 (-0.01), AMGN: 158.70 (-2.15), ABBV: 63.25 (-0.38), REGN: 399.88 (-2.75)

Earnings Triple Plays
Bespoke Investment Group - Seeking Alpha - Wed Nov 12, 1:54AM CST
The third quarter earnings season unofficially comes to an end on Thursday when Wal-Mart (NYSE: WMT ) reports earnings before the open. So far this earnings season, more than 2,000 companies have reported their quarterly numbers, and our job here is...
GD: 141.97 (-0.74), ACT: 244.25 (+2.62), CBG: 32.45 (-0.24), HCP: 43.58 (-0.34), BCR: 164.69 (-0.90), PCG: 49.87 (+0.10), AMGN: 158.70 (-2.15), CB: 101.57 (+0.10), SRE: 109.21 (-0.30), PLD: 41.03 (-0.07), HSP: 57.46 (-0.63), TWX: 79.34 (+0.36), KIM: 24.63 (-0.11), CMI: 143.84 (-0.68), ALXN: 190.28 (-3.31), ESS: 200.29 (-0.23), ABBV: 63.25 (-0.38), CAT: 100.72 (-0.39), AAPL: 113.16 (+0.34)

Bristol-Myers Gives Updates on HCV Candidate Daclatasvir - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 5:41PM CST
Bristol-Myers Squibb Company (BMY) provided an update on its hepatitis C (HCV) candidate daclatasvir.
AGN: 196.51 (+0.30), GILD: 102.12 (-2.08), ABBV: 63.25 (-0.38), BMY: 57.47 (-0.33)

Galapagos - AbbVie's Best Bet For Staying Market Leader In Rheumatoid Arthritis Post Humira?
SNJBiostoxx - at Seeking Alpha - Tue Nov 11, 2:45PM CST

ABBV: 63.25 (-0.38)

Re-Examining My Bullish Thesis On Walgreen
Alexander J. Poulos - at Seeking Alpha - Tue Nov 11, 1:04PM CST

SHPG: 201.15 (-1.27), PFE: 30.47 (+0.05), AZN: 72.95 (-1.58), ABBV: 63.25 (-0.38), WAG: 66.99 (+0.03)

Why Is Gilead Always Holding The Ace? A Prediction Of The Future HCV Market And What Analysts Aren't Talking About
Pharma Doc - Seeking Alpha - Tue Nov 11, 10:13AM CST
No matter when you've followed Gilead (NASDAQ: GILD ) over the past decade, they always seem to be holding the ace. Whether in the HIV arena or now in HCV, the Gilead management is always one step ahead and is planning to dominate its market. Gilead...
GILD: 102.13 (-2.07), ACHN: 13.88 (+0.39), MRK: 59.34 (-0.20), ABBV: 63.25 (-0.38), BMY: 57.47 (-0.33)

Gilead presents Harvoni data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:03AM CST

JNJ: 108.69 (-0.38), GILD: 102.13 (-2.07), ACHN: 13.88 (+0.39), CNAT: 7.05 (-0.10), MRK: 59.34 (-0.20), RGLS: 17.39 (-0.35), ABBV: 63.25 (-0.38), BMY: 57.47 (-0.33), ENTA: 43.20 (-0.02)

Are Expensive Biotech Drugs Bad For Business?
Keith Williams - at Seeking Alpha - Tue Nov 11, 9:45AM CST

VRTX: 112.37 (-0.35), GILD: 102.13 (-2.07), MRK: 59.34 (-0.20), DNDN: 0.12 (-0.01), AZN: 72.94 (-1.59), TEVA: 57.14 (-0.03), ABBV: 63.25 (-0.38), GSK: 45.64 (-0.02), BMY: 57.49 (-0.31), NVS: 93.52 (-0.86)

Stock Market News for November 11, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 9:10AM CST
Benchmarks posted modest gains on Monday, boosted by a rally in healthcare and transportation stocks
NFLX: 379.56 (+0.15), YHOO: 50.69 (+0.19), AMZN: 321.65 (+5.17), BIIB: 311.18 (-6.80), VRTX: 112.37 (-0.35), FEYE: 32.95 (-0.39), LNKD: 230.94 (+1.17), EBAY: 54.23 (-0.14), GILD: 102.13 (-2.07), AMGN: 158.70 (-2.15), ABBV: 63.25 (-0.38), REGN: 399.88 (-2.75), CELG: 105.74 (-1.69)

AbbVie presents HCV/HIV and liver transplant HCV data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 9:07AM CST

JNJ: 108.69 (-0.38), GILD: 102.13 (-2.07), ACHN: 13.88 (+0.39), CNAT: 7.05 (-0.10), MRK: 59.34 (-0.20), RGLS: 17.46 (-0.28), ABBV: 63.25 (-0.38), BMY: 57.49 (-0.31), ENTA: 43.20 (-0.02)

AbbVie Inc. (ABBV) Stock Research Links

ABBV Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ALS.Community Launches Free Online Support Platform

A Long Path to Connection Sometimes it's easy to forget the power a community can wield until you see one rally around a cause. The launch of ALS.Community isn't just a digital debut; it's a testament to how collective understanding can be a lifeline. For folks grappling with amyotrophic lateral sclerosis (ALS), beating solitude is often half the battle. Founder Jeff...

Parents as Teachers Podcast: Anthem Awards Finalist

Celebrating Impact Through Parenthood Narratives Blending heartfelt stories with educational insights, the Parents as Teachers Podcast stands tall as a Finalist in two categories of the 6th Annual Anthem Awards. Recognizing achievements in Content & Media for both Education, Art & Culture and Health, this nod acknowledges the profound impact being made on family...

De¹ Unveils Tokenization Model on BNB Chain

De¹'s Bold Move into Enhanced Digital Finance Just when you thought the financial landscape couldn’t get any more complex, De¹ steps into the ring with its Tokenized Asset World on the BNB Chain—a move that's stirring the pot of tokenized finance in more ways than one. For old-school investors who thrive on waving outlandish stock bets, this crypto narrative is a...

Moore Law Urges Millrose Investors: Join the Action

Is Millrose Playing a Risky Game? When I caught wind of this latest debacle with Millrose Properties, Inc. (NYSE: MRP), my gut reaction was a mix of curiosity and skepticism. Hunterbrook Media's report just blasted across the headlines, digging up some dirt on Millrose's recent financial maneuvers. Apparently, these cats have been busy buying homes to the tune of $200...

Tumor Ablation Market: Charting a Billion-Dollar Surge

Cancer's Unforgiving Climb: Opportunity Amidst Challenge Looking at the current state of the global tumor ablation market, one thing's clear—it's on a sort of upward swing you'd expect trains to make, riding the rails of rising cancer rates and technological advancements. At least that's what the folks at Wissen Research are banking on, projecting a leap to $1.8 billion...

Nest Health Appoints Peter Morrison for Multistate Expansion

Peter Morrison Steps Up as Chief Growth Officer You know, it's not every day you see a move as gutsy as Nest Health's recent appointment of Peter Morrison. They're shaking up the Medicaid space, aiming to redefine primary care for families with limited resources. Morrison, coming from heavyweights like UnitedHealthcare and Centene, isn't your typical pencil-pusher. He’s...

Shadeform's Spot: Monetizing Idle GPU Resources

Shadeform's Spot Aims To Cut GPU Waste Imagine letting money burn while your GPUs sit in idle mode. That's the reality for many in the cloud computing sector, and Shadeform looks ready to tackle this inefficiency head-on. The launch of Spot, by the GPU Cloud Marketplace Shadeform, offers a novel way to make sure every floating gigaflop translates into some form of...

DARPA Pumps $10.7M into RxMP's Hemorrhage Control Drug

RxMP Therapeutics Lands a DARPA Deal Would you look at that—RxMP Therapeutics just got handed a load of cash thanks to some good old government backing. Up to $10.7 million from DARPA is no chump change. It's like finding a lifeboat right when you're treading water out there in the big bad sea. This award under the RAPIID program is set to move the needle for RxMP’s...

New JPA Aims to Energize Inland Empire's Water Supply

Fresh Steps in San Bernardino's Infrastructure Strategy Here's a twist for you: public agencies in San Bernardino County decided enough with the same old, same old and cooked up a new joint powers authority (JPA). They call it the San Bernardino Water and Power Authority, which sounds snappy enough for a meeting room nameplate, I reckon. Who's Steering the Ship? Leading...

PetroCal Drives Dual Mandate for Orlando Car Wash

PetroCal's Double Play in the Real Estate Game When you've been in this game as long as I have, you learn to keep an eye on players who can juggle multiple roles. And that's exactly what PetroCal Associates has pulled off with the Tommy's Express Car Wash project in Orlando. This isn't just another carwash setup, folks. We're talking about integrating into Unicorp...